Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Xing-Ming Ye"'
Publikováno v:
Biochemical and Biophysical Research Communications. 496:1308-1313
Breast cancer resistance to the monoclonal erbB2/HER2 antibody trastuzumab (or herceptin) has become a significant obstacle in clinical targeted therapy of HER2-positive breast cancer. Previous research demonstrated that such drug resistance may be r
Autor:
Xing-Ming Ye1,2 yexingming1984@126.com, Hua-Yu Zhu1 zzhuhy@aliyun.com, Wen-Dong Bai3 bwddcgzl@163.com, Ting Wang1 wtingbio@163.com, Lei Wang1 fenglei_1@163.com, Ying Chen2 fjbccy@hotmail.com, An-Gang Yang3 agyang@fmmu.edu.cn, Lin-Tao Jia1 jialth@fmmu.edu.cn
Publikováno v:
BMC Cancer. 2014, Vol. 14 Issue 1, p1-22. 22p.
Autor:
Wen-Dong Bai, Angang Yang, Xing-Ming Ye, Huayu Zhu, Jing Zhao, Lin-Tao Jia, Lei Wang, Ying Chen, Xiao Zhang
Publikováno v:
BMB Reports
HER2-overexpressing breast cancers are characterized by frequent distant metastasis and often develop resistance after short-term effective treatment with the monoclonal antibody drug, trastuzumab. Here, we found that the oncogenic miRNA, miR-221, in
Autor:
Xing-Ming Ye, Meng-Yao Zhang, Huayu Zhu, Angang Yang, Wen-Dong Bai, Xun Huang, Lin-Tao Jia, Jiao Zhao, Bin Gu, Guoxu Zheng, Wenjin Xi
Publikováno v:
International Journal of Cancer. 135:1356-1368
Resistance to trastuzumab and concomitantly distal metastasis are leading causes of mortality in HER2-positive breast cancers, the molecular basis of which remains largely unknown. Here, we generated trastuzumab-resistant breast cancer cells with inc
Autor:
Wen-Dong, Bai, Xing-Ming, Ye, Meng-Yao, Zhang, Hua-Yu, Zhu, Wen-Jin, Xi, Xun, Huang, Jiao, Zhao, Bin, Gu, Guo-Xu, Zheng, An-Gang, Yang, Lin-Tao, Jia
Publikováno v:
International journal of cancer. 135(6)
Resistance to trastuzumab and concomitantly distal metastasis are leading causes of mortality in HER2-positive breast cancers, the molecular basis of which remains largely unknown. Here, we generated trastuzumab-resistant breast cancer cells with inc
Autor:
Angang Yang, Lin-Tao Jia, Ying Chen, Ting Wang, Lei Wang, Xing-Ming Ye, Huayu Zhu, Wen-Dong Bai
Publikováno v:
BMC Cancer
Background Resistance to humanized monoclonal erbB2/HER2 antibody, trastuzumab (Herceptin), has become a pivotal obstacle for targeted therapy of HER2-positive breast cancers. The activation of alternative growth factor receptors, in particular, the